Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 (Yahoo Finance) - Sep 8, 2026 - "Tinlarebant will be reviewed under the Sakigake Designation System - Japan's expedited regulatory pathway for innovative medical products."
Japan filing • Japanese regulatory • Inherited Retinal Dystrophy
|